Hepatitis C virus (HCV) related liver fibrosis in people who inject drugs (PWID) at the Stockholm Needle Exchange – evaluated with liver elasticity

References

• The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176.
   PubMed Web of Science ®Google Scholar
• Wiessing L, Ferri M, Grady B, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PloS One. 2014;9:e103345.
   PubMed Web of Science ®Google Scholar
• Palmateer N, Hutchinson S, McAllister G, et al. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. J Viral Hepat. 2014;21:25–32.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Charlson F, Stanaway J, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16:1385–1398.
   PubMed Web of Science ®Google Scholar
• Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol. 2017;14:641–651.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global health sector strategy on viral hepatitis 2016-2021, towards ending viral hepatitis. Geneva: World Health Organization; 2016.
   Google Scholar
• Marshall AD, Pawlotsky JM, Lazarus JV, et al. The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat. J Hepatol. 2018;69(5):1188–1196.
   Web of Science ®Google Scholar
• Kaberg M, Hammarberg A, Lidman C, et al. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program. Infect Dis. 2017;49:728–736.
   PubMed Web of Science ®Google Scholar
• Kaberg M, Naver G, Hammarberg A, et al. Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination. J Viral Hepat. 2018;25(12):1452-1461.
   PubMed Web of Science ®Google Scholar
• Lagging M, Wejstal R, Norkrans G, et al. Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. Infect Dis. 2017;49:561–575.
   PubMed Web of Science ®Google Scholar
• Referensgruppen för antiviral terapi (RAV). [Treatment of hepatitis C virus infection: updated Swedish Guidelines 2017] 2017. [cited 2018 Sep 28]. Available from: https://www.sls.se/rav/rekommendationer/hepatit-c-virus/.
   Google Scholar
• Kåberg M, Lindström F. [The Stockholm Needle Exchange - Annual Report 2017] 2017. [cited 2018 Aug 25]. Available from: http://dok.slso.sll.se/BeroendeC/verksamhetsberattelse_sprututbytesmottagningen_2017.pdf.
   Google Scholar
• Afdhal NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol. 2012;8:605–607.
   PubMedGoogle Scholar
• European Association for the Study of the Liver. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–264.
   PubMed Web of Science ®Google Scholar
• Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835–847.
   PubMed Web of Science ®Google Scholar
• Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med. 2013;158:807–820.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatol. 2006;43:1317–1325.
   PubMed Web of Science ®Google Scholar
• Reinert DF, Allen JP. The alcohol use disorders identification test: an update of research findings. Alcoholism Clin Exp Res. 2007;31:185–199.
   PubMed Web of Science ®Google Scholar
• Aradottir S, Asanovska G, Gjerss S, et al. PHosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol Alcohol. 2006;41:431–437.
   PubMed Web of Science ®Google Scholar
• Walther L, de Bejczy A, Lof E, et al. Phosphatidylethanol is superior to carbohydrate-deficient transferrin and gamma-glutamyltransferase as an alcohol marker and is a reliable estimate of alcohol consumption level. Alcohol Clin Exp Res. 2015;39:2200–2208.
   PubMed Web of Science ®Google Scholar
• Helander A, Hansson T. National harmonization of the alcohol biomarker PEth. Lakartidningen. 2013;110:1747–1748.
   PubMedGoogle Scholar
• The World Health Organization (WHO). Body mass index - BMI 2018. [cited 2018 Aug 25]. Available from: http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi.
   Google Scholar
• Marshall AD, Micallef M, Erratt A, et al. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: the LiveRLife Study. Int J Drug Policy. 2015;26:984–991.
   PubMed Web of Science ®Google Scholar
• Crowley D, Cullen W, Laird E, et al. Exploring patient characteristics and barriers to hepatitis C treatment in patients on opioid substitution treatment attending a community based fibro-scanning clinic. J Transl Int Med. 2017;5:112–119.
   PubMed Web of Science ®Google Scholar
• Bloom S, Kemp W, Nicoll A, et al. Liver stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver-related events in hepatitis C. J Hepatol. 2018;69:575–583.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Glantz M, Evans-Lacko S, et al. Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys. World Psychiatry. 2017;16:299–307.
   PubMed Web of Science ®Google Scholar
• Cunningham JA, Breslin FC. Only one in three people with alcohol abuse or dependence ever seek treatment. Addict Behav. 2004;29:221–223.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Alcohol and Drug Use Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018.
   Web of Science ®Google Scholar
• Alavi M, Janjua NZ, Chong M, et al. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: an international study. J Hepatol. 2018;68:393–401.
   PubMed Web of Science ®Google Scholar
• Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatol. 1998;28:805–809.
   PubMed Web of Science ®Google Scholar
• Hedenstierna M, Nangarhari A, El-Sabini A, et al. Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C. J Viral Hepat. 2018;25:802–810.
   PubMed Web of Science ®Google Scholar
• Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int. 2009;29:89–99.
   PubMed Web of Science ®Google Scholar
• EASL Recommendations. Treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511.
   PubMed Web of Science ®Google Scholar
• Australian recommendations for the management of hepatitis C virus infection: a consensus statement (September 2018) 2018. [cited 2018 Sep 28]. Available from: https://www.hepatitisaustralia.com/guidleines/.
   Google Scholar
• Dillon J, editor. Task shifting - what to shift and how to do it. Cascais: Presentation at INHSU 2018; 2018.
   Google Scholar
• Westin J, Ydreborg M, Islam S, et al. A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scand J Gastroenterol. 2008;43:73–80.
   PubMed Web of Science ®Google Scholar
• Drobnik A, Judd C, Banach D, et al. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health. 2011;101:2151–2155.
   PubMed Web of Science ®Google Scholar
• Hickman M, McDonald T, Judd A, et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat. 2008;15:250–254.
   PubMed Web of Science ®Google Scholar